Current Report Filing (8-k)
May 21 2021 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 18, 2021
GUARDION
HEALTH SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38861
|
|
47-4428421
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
15150
Avenue of Science, Suite 200
San
Diego, CA 92128
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (858) 605-9055
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
GHSI
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01. Entry into a Material Definitive Agreement.
On
May 18, 2021, Guardion Health Sciences, Inc. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase
Agreement”) by and among the Company, Adare Pharmaceuticals, Inc., a Nevada corporation (the “Seller”), and Activ Nutritional,
LLC, a Delaware limited liability company (“Activ Nutritional”), pursuant to which the Company agreed to purchase all of
the issued and outstanding equity securities of Activ Nutritional from the Seller (the “Acquisition”).
Activ
Nutritional owns the Viactiv® line of supplement chews for bone health, immune health and other applications. Currently marketed
through many of the nation’s largest retailers, including, among others, Walmart (retail and online), Target and Amazon, the Viactiv
product lines are expected to become Guardion’s most prominent product lines, as well as to provide access to significant opportunities
in the short-term for growth and expansion.
The
total purchase price payable by the Company for the Acquisition is $26 million in cash, subject to certain adjustments as provided in
the Purchase Agreement based on transaction expenses, cash and cash equivalents, indebtedness and net working capital of Activ Nutritional
at the closing of the Acquisition (the “Closing”). The Company expects the transaction to close by June 30, 2021. The Closing
is subject to the satisfaction or waiver of certain customary conditions. The Purchase Agreement contains customary representations and
warranties regarding the Company and the Seller, and customary covenants of the Company and the Seller. The representations and warranties
in the Purchase Agreement terminate at, and do not survive, the Closing.
The
foregoing description of the Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is qualified
in its entirety by reference to the Purchase Agreement, a copy of which is filed as Exhibit 10.1 hereto and is hereby incorporated into
this report by reference. The Purchase Agreement has been included to provide shareholders and investors with information regarding its
terms. It is not intended to provide any other factual information about the Company, the Seller or Activ Nutritional. In particular,
the assertions embodied in the representations and warranties contained in the Purchase Agreement are subject to qualifications and limitations
agreed to by the respective parties in connection with negotiating the terms of the Purchase Agreement, including information contained
in a confidential disclosure schedule provided by the Seller and Activ Nutritional to the Company in connection with the signing of the
Purchase Agreement. The confidential disclosure schedule contains information that modifies, qualifies and creates exceptions to the
representations and warranties set forth in the Purchase Agreement. Moreover, certain representations and warranties in the Purchase
Agreement were used for the purpose of allocating risk between the Company and the Seller rather than establishing matters as facts.
Accordingly, shareholders and investors should not rely on the representations and warranties in the Purchase Agreement as characterizations
of the actual state of facts about the Company, the Seller, or Activ Nutritional.
Item
8.01. Other Events.
On
May 18, 2021, the Company issued a press release announcing the execution of the Equity Purchase Agreement. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
GUARDION
HEALTH SCIENCES, INC.
|
Date:
May 21, 2021
|
|
|
|
By:
|
/s/
Bret Scholtes
|
|
Name:
|
Bret
Scholtes
|
|
Title:
|
Chief
Executive Officer
|
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024